Healthcare - Biotechnology - NASDAQ - US
$ 0.05
-37.5 %
$ 8.89 M
Market Cap
-0.01
P/E
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.[ Read More ]
The intrinsic value of one NRXPW stock under the base case scenario is HIDDEN Compared to the current market price of 0.05 USD, NRx Pharmaceuticals, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart NRXPW
FINANCIALS
0
REVENUE
-27.6 M
OPERATING INCOME
-30.2 M
NET INCOME
-21.7 M
OPERATING CASH FLOW
-3 K
INVESTING CASH FLOW
6.2 M
FINANCING CASH FLOW
0
REVENUE
-3.02 M
OPERATING INCOME
-1.62 M
NET INCOME
-1.36 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
2.05 M
FINANCING CASH FLOW
Balance Sheet Decomposition
NRx Pharmaceuticals, Inc.
| Current Assets | 6.88 M |
| Cash & Short-Term Investments | 4.6 M |
| Receivables | 0 |
| Other Current Assets | 2.29 M |
| Non-Current Assets | 431 K |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 431 K |
| Current Liabilities | 19 M |
| Accounts Payable | 4.63 M |
| Short-Term Debt | 9.16 M |
| Other Current Liabilities | 5.26 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
NRx Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 5 K |
| Gross Profit | -5 K |
| Operating Expenses | 27.6 M |
| Operating Income | -27.6 M |
| Other Expenses | 2.56 M |
| Net Income | -30.2 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
256.97%
ROE
-412.17%
ROA
1072.27%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
NRx Pharmaceuticals, Inc.
| Net Income | -30.2 M |
| Depreciation & Amortization | 5 K |
| Capital Expenditures | -3 K |
| Stock-Based Compensation | 387 K |
| Change in Working Capital | 5.16 M |
| Others | 5.45 M |
| Free Cash Flow | -21.7 M |
Wall Street Analysts Price Targets
NRx Pharmaceuticals, Inc.
NRXPW has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
NRx Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Aug 30, 2023
|
Bought 11.2 K USD
|
Gorovitz Aaron
Director |
+ 35000
|
0.3199 USD |
|
1 year ago
Aug 30, 2023
|
Bought 20.1 K USD
|
Hurvitz Chaim
Director |
+ 70000
|
0.2875 USD |
|
1 year ago
Aug 23, 2023
|
Bought 33 K USD
|
Javitt Jonathan C
Chief Scientist |
+ 100000
|
0.33 USD |
|
1 year ago
Aug 22, 2023
|
Bought 64.4 K USD
|
Javitt Jonathan C
Chief Scientist |
+ 200000
|
0.322 USD |
|
1 year ago
Dec 16, 2022
|
Bought 58.5 K USD
|
Willard Stephen H
director: CHIEF EXECUTIVE OFFICER |
+ 50000
|
1.17 USD |
|
1 year ago
Dec 16, 2022
|
Bought 33 K USD
|
VAN VOORHEES SETH
director: CHIEF FINANCIAL OFFICER |
+ 30000
|
1.1 USD |
|
1 year ago
Nov 25, 2022
|
Bought 7.79 K USD
|
VAN VOORHEES SETH
director: CHIEF FINANCIAL OFFICER |
+ 7021
|
1.11 USD |
|
1 year ago
Nov 25, 2022
|
Bought 660 USD
|
VAN VOORHEES SETH
director: CHIEF FINANCIAL OFFICER |
+ 600
|
1.1 USD |
|
1 year ago
Nov 25, 2022
|
Bought 9.76 K USD
|
VAN VOORHEES SETH
director: CHIEF FINANCIAL OFFICER |
+ 8716
|
1.12 USD |
|
1 year ago
Dec 07, 2022
|
Sell 400 K USD
|
Javitt Jonathan C
Director |
- 400000
|
1 USD |
|
1 year ago
Nov 29, 2022
|
Sell 20.7 K USD
|
Javitt Daniel C.
Director |
- 13730
|
1.5041 USD |
|
1 year ago
Nov 30, 2022
|
Sell 12.7 K USD
|
Javitt Daniel C.
Director |
- 8441
|
1.5046 USD |
|
1 year ago
Nov 28, 2022
|
Bought 3.1 K USD
|
Flynn Patrick John
Director |
+ 2500
|
1.24 USD |
|
1 year ago
Nov 28, 2022
|
Bought 3.12 K USD
|
Flynn Patrick John
Director |
+ 2500
|
1.25 USD |
|
1 year ago
Nov 28, 2022
|
Bought 2.19 K USD
|
Flynn Patrick John
Director |
+ 1750
|
1.25 USD |
|
1 year ago
Nov 25, 2022
|
Bought 7.79 K USD
|
VAN VOORHEES SETH
director: CHIEF FINANCIAL OFFICER |
+ 7021
|
1.11 USD |
|
1 year ago
Nov 25, 2022
|
Bought 660 USD
|
VAN VOORHEES SETH
director: CHIEF FINANCIAL OFFICER |
+ 600
|
1.1 USD |
|
1 year ago
Nov 25, 2022
|
Bought 9.76 K USD
|
VAN VOORHEES SETH
director: CHIEF FINANCIAL OFFICER |
+ 8716
|
1.12 USD |
|
2 years ago
Nov 18, 2022
|
Bought 44.4 K USD
|
Hurvitz Chaim
Director |
+ 40408
|
1.1 USD |
|
2 years ago
Nov 17, 2022
|
Bought 186 K USD
|
Hurvitz Chaim
Director |
+ 171780
|
1.08 USD |
|
2 years ago
Nov 16, 2022
|
Bought 285 K USD
|
Hurvitz Chaim
Director |
+ 287812
|
0.99 USD |
|
2 years ago
Nov 18, 2022
|
Bought 44.4 K USD
|
Hurvitz Chaim
Director |
+ 40408
|
1.1 USD |
|
2 years ago
Nov 17, 2022
|
Bought 186 K USD
|
Hurvitz Chaim
Director |
+ 171780
|
1.08 USD |
|
2 years ago
Nov 16, 2022
|
Bought 285 K USD
|
Hurvitz Chaim
Director |
+ 287812
|
0.99 USD |
|
2 years ago
Nov 16, 2022
|
Sell 136 K USD
|
Javitt Daniel C.
Director |
- 133719
|
1.02 USD |
|
2 years ago
Nov 17, 2022
|
Sell 34.7 K USD
|
Javitt Daniel C.
Director |
- 33018
|
1.0523 USD |
|
2 years ago
Nov 11, 2022
|
Sell 49.5 K USD
|
Javitt Daniel C.
Director |
- 49200
|
1.0063 USD |
7. News
8. Profile Summary
NRx Pharmaceuticals, Inc. NRXPW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 8.89 M
Dividend Yield
0.00%
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Contact
1201 Orange Street, Wilmington, DE, 19801
https://www.nrxpharma.com
IPO Date
Dec. 1, 2017
Employees
None
Officers
Mr. Matthew Patrick Duffy
Chief Business Officer & Co-Chief Executive Officer of Hope Therapeutics
Mr. Richard Clavano Narido
Chief Financial Officer & Treasurer
Suzanne Messere
Investor Relations
Dr. Jonathan C. Javitt M.D., M.P.H.
Co-Founder, Chief Scientist Officer, Chairman & Interim Chief Executive Officer
Dr. Riccardo Panicucci Ph.D.
Chief Manufacturing & Technology Officer
Dr. Philip T. Lavin Ph.D.
Chief Methodologist